Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma

Melanoma Research

Volumn 23, Issue 3, 2013, Pages 218-220

  Gambichler, Thilo ^a   Sand, Michael ^a   Skrygan, Marina ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

5 hydroxymethylcytosine; 5 methylcytosine; epigenetic regulation; malignant melanoma; ten eleven translocation 2 protein

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; REGULATOR PROTEIN; TEN ELEVEN TRANSLOCATION 2 PROTEIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BENIGN COMPOUND NEVUS; DYSPLASTIC COMPOUND NEVUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MELANOMA; NEVUS; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERFICIAL SPREADING MELANOMA;

CYTOSINE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; EPIGENOMICS; HUMANS; MELANOMA; PARAFFIN EMBEDDING; PROTO-ONCOGENE PROTEINS; SKIN NEOPLASMS; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84877080268     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835f9bd4     Document Type: Article

References (9)

1. Dumitrescu RG, Verma M (eds.). Methods in molecular biology. Cancer epigenetics. New York, Dordrecht, Heidelberg, London: Springe.r.
2. Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development 2012; 139:1895-1902.
3. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013; 32:663-669.
4. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011; 2:627-637.
5. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, et al. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 2011; 71:7360-7365.
6. Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci 2012; 103:670-676.
7. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468:839-843.
8. Kraus TF, Globisch D,Wagner M, Eigenbrod S,Widmann D, Mu nzel M, et al. Low values of 5-hydroxymethylcytosine (5hmC), the 'sixth base,' are associated with anaplasia in human brain tumors. Int J Cancer 2012; 131:1577-1590.
9. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012; 150:1135-1146.